• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Cowen Healthcare Investments

Cowen Healthcare Investments was founded to capitalize on the tremendous pace of change and innovation in the healthcare sector. The team has considerable biopharma investing experience and a disciplined investment history driven by deep diligence of underlying science. Cowen Healthcare Investments principally invests in mid- to late-stage private biopharma and digital health companies with scientifically validated targets, compounds, and technologies. We focus on companies with disruptive science, targeting a significant unmet medical need, and experienced management teams. *

 

	Start	2017-12-20 existent
	Group	Cowen (Group)
	Industry	finance
	Industry 2	healthcare
	Region	New York, NY
	Country	United States (USA)
	City	n. a. New York, NY
		Address record changed: 2021-02-25
Basic data	Employees	n. a.
		* Document for �About Section�: Orchard Therapeutics Ltd.. (12/20/17). "Press Release: Orchard Therapeutics Announces $110m Series B Financing to Advance Transformative Gene Therapy Pipeline". London.
		Record changed: 2022-05-24

Advertisement

More documents for Cowen (Group)

• [1] Compass Pathways plc. (4/30/21). "Press Release: Compass Pathways Announces Pricing of Public Offering". London....
• [2] Compass Pathways plc. (4/27/21). "Press Release: Compass Pathways Launches Proposed Public Offering". London....
• [3] VectivBio AG. (10/15/20). "Press Release: VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases". Basel....
• [4] Argenx SE. (5/29/20). "Press Release: Argenx Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs". Breda & Ghent....
• [5] Argenx SE. (5/28/20). "Press Release: Argenx Raises $750 Million in Gross Proceeds in a Global Offering". Breda & Ghent....
• [6] Oxford Nanopore Technologies Ltd.. (5/26/20). "Press Release: Oxford Nanopore Announces £48.4M ($59.2M) in New Capital to Support Ongoing Innovation and the Rapid Worldwide Growth of Nanopore Sequencing". Oxford....
• [7] AM-Pharma B.V.. (3/31/20). "Press Release: AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI". Utrecht....
• [8] Oncorus, Inc.. (8/21/19). "Press Release: Oncorus Announces $79.5 Million Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors". Cambridge, MA....
• [9] Orchard Therapeutics Ltd.. (3/4/19). "Press Release: Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019". Boston, MA & London....
• [10] Argenx SE. (3/4/19). "Press Release: Argenx to Present at Cowen and Company 39th Annual Health Care Conference". Breda & Ghent....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.